Post-marketing Study to Collect Safety Data in Heart Transplant Patients Receiving Everolimus

A Non-interventional Protocol to Collect Prospective and Retrospective Data in Patients Receiving Everolimus to Prevent Acute Rejection Following Cardiac Transplantation

The purpose of this observational protocol is to evaluate the use of everolimus in routine clinical practice for heart transplants.

Primary outcome measures: incidence of acute rejection episodes Secondary outcomes: safety

Inclusion Criteria:

• Cardiac transplant recipients
• Discharged alive from hospital
• Must be receiving everolimus

Exclusion Criteria:

• Patients not treated with everolimus beginning within 2 weeks after receiving a heart transplant

Other inclusion/exclusion criteria may apply.